1
|
Zhong L, Xu L, Liu Y, Li Q, Zhao D, Li Z, Zhang H, Zhang H, Kan Q, Wang Y, Sun J, He Z. Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy. Acta Pharm Sin B 2019; 9:397-409. [PMID: 30972285 PMCID: PMC6437598 DOI: 10.1016/j.apsb.2018.11.006] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 10/02/2018] [Accepted: 11/02/2018] [Indexed: 02/07/2023] Open
Abstract
Hyaluronic acid (HA) is a natural ligand of tumor-targeted drug delivery systems (DDS) due to the relevant CD44 receptor overexpressed on tumor cell membranes. However, other HA receptors (HARE and LYVE-1) are also overexpressing in the reticuloendothelial system (RES). Therefore, polyethylene glycol (PEG) modification of HA-based DDS is necessary to reduce RES capture. Unfortunately, pegylation remarkably inhibits tumor cellular uptake and endosomal escapement, significantly compromising the in vivo antitumor efficacy. Herein, we developed a Dox-loaded HA-based transformable supramolecular nanoplatform (Dox/HCVBP) to overcome this dilemma. Dox/HCVBP contains a tumor extracellular acidity-sensitive detachable PEG shell achieved by a benzoic imine linkage. The in vitro and in vivo investigations further demonstrated that Dox/HCVBP could be in a "stealth" state at blood stream for a long circulation time due to the buried HA ligands and the minimized nonspecific interaction by PEG shell. However, it could transform into a "recognition" state under the tumor acidic microenvironment for efficient tumor cellular uptake due to the direct exposure of active targeting ligand HA following PEG shell detachment. Such a transformative concept provides a promising strategy to resolve the dilemma of natural ligand-based DDS with conflicting two processes of tumor cellular uptake and in vivo nonspecific biodistribution.
Collapse
Key Words
- AD-B-PEG, the pH-responsive adamantane-PEG conjugate
- AD-O-PEG, the non-pH sensitive adamantane-PEG conjugate
- ADA, 1-adamantane carboxylic acid
- AUC, area under the plasma concentration—time curve
- Active-targeting
- Benzoic imine linkage
- CLSM, confocal laser scanning microscope
- Cancer therapy
- DAPI, 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride
- DCC, N,N′-dicyclohexylcarbodiimide
- DCM, dichloromethane
- DDS, drug delivery systems
- DL, drug-loading content
- DLS, dynamic light scattering
- DMAP, 4-dimethylaminopyrideine
- DMEM, Dulbecco׳s modified Eagle׳s medium
- DiR, 1,1′-dioctadecyltetramethyl indotricarbocyanine iodide
- Dox/HCVBP, Dox-loaded hyaluronic acid-based transformable supramolecular nanoplatform
- Dox/HCVOP, Dox-loaded hyaluronic acid-based untransformable supramolecular nanoplatform
- Dox·HCl, doxorubicin hydrochloride
- EDC, 1-ethyl-3-(3-dimethyalminopropl) carbodiimide
- EE, encapsulation efficiency
- FBS, fetal bovine serum
- H&E, hematoxylin and eosin
- HA, hyaluronic acid
- HA-CD, hydroxypropyl-β-cyclodextrin grafted hyaluronic acid polymer
- HCBP, hydroxypropyl-β-cyclodextrin grafted hyaluronic acid polymer and pH-responsive adamantane-PEG conjugate inclusion complex
- HCPs, hydroxypropyl-β-cyclodextrin grafted hyaluronic acid polymer and adamantane-PEG conjugate inclusion complexes
- HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesul-fonic acid
- HOBT, 1-hydroxybenzotriazole
- HPCD, hydroxypropyl-β-cyclodextrin
- Hyaluronic acid
- MW, molecular weight
- NPs, nanoparticles
- Natural ligand
- PCC, Pearson׳s correlation coefficient
- PDI, polydispersity index
- PEG dilemma
- RES, reticuloendothelial system
- RPMI-1640, Roswell Park Memorial Institute-1640
- Supramolecular nanoplat-form
- THF, tetrahydrofuran
- TUNEL, terminal deoxynucleotidyl transferased dUTP nick end labeling
- Transformative nanoparti-cles
- VES, vitamin E succinate
- pHe, the extracellular pH
Collapse
Affiliation(s)
- Lu Zhong
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Lu Xu
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Yanying Liu
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Qingsong Li
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Dongyang Zhao
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Zhenbao Li
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Huicong Zhang
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Haotian Zhang
- Department of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Qiming Kan
- Department of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Yongjun Wang
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Jin Sun
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Zhonggui He
- Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
| |
Collapse
|